Advertisement

Antimicrobials

  • Edward J. Blanchard
  • Rafik Samuel
  • Wissam Chatila
Chapter

Abstract

Recognize the different classes of antimicrobials used in the critical care setting. Understand the mechanisms of action and pharmacology of the various classes of antimicrobials. Identify the spectrum of coverage for specific antimicrobials. Describe possible adverse effects and drug interactions caused by antimicrobials. Select appropriate antimicrobials for various pathogens.

Keywords

Intensive Care Unit Minimal Inhibitory Concentration Renal Insufficiency Herpes Zoster Varicella Zoster Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Falagas ME et al. Risk factors for isolation of strains susceptible only to polymyxin among patients with Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2006;50(7):2541-2543.PubMedCrossRefGoogle Scholar
  2. 2.
    Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40(9):1333-1341.PubMedCrossRefGoogle Scholar
  3. 3.
    Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis. 2005;41(suppl 5):S303-S314.PubMedCrossRefGoogle Scholar
  4. 4.
    Peleg AY et al. Acinetobacter baumanii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother. 2007;59(1):128-131.PubMedCrossRefGoogle Scholar
  5. 5.
    Tenover FC, Moellering RC. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis. 2007;44(9):1208-1215.PubMedCrossRefGoogle Scholar
  6. 6.
    Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis. 2003;36(4):473-481.PubMedCrossRefGoogle Scholar
  7. 7.
    Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis. 2004;38(7):994-1000.PubMedCrossRefGoogle Scholar
  8. 8.
    Stevens DL, Bryant AE, Yan S. Invasive group A streptococcal infection: new concepts in antibiotic treatment. Int J Antimicrob Agents. 1994;4:297.PubMedCrossRefGoogle Scholar
  9. 9.
    Ferriols-Lisart R, Alos-Alminana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health Syst Pharm. 1996;53:1141.PubMedGoogle Scholar
  10. 10.
    Orozco AS et al. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother. 1998;42(10):2645-2649.PubMedGoogle Scholar
  11. 11.
    Spellberg BJ, Filler SG, Edwards JE. Current treatment strategies for disseminated candidiasis. Clin Infect Dis. 2006;42(2):244-251.PubMedCrossRefGoogle Scholar
  12. 12.
    Herbrecht R et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408-415.PubMedCrossRefGoogle Scholar
  13. 13.
    Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36(5):630-637.PubMedCrossRefGoogle Scholar
  14. 14.
    Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad spectrum triazole antifungal agent. Clin Infect Dis. 2007;45(12):1610-1617.PubMedCrossRefGoogle Scholar
  15. 15.
    Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis. 2003;36(11):1445-1457.PubMedCrossRefGoogle Scholar
  16. 16.
    Walsh TJ et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med. 1999;340(10):764-771.PubMedCrossRefGoogle Scholar
  17. 17.
    Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis. 2006;42(8):1171-1178.PubMedCrossRefGoogle Scholar
  18. 18.
    Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin Infect Dis. 2006;43(2):215-222.PubMedCrossRefGoogle Scholar
  19. 19.
    Jabs DA et al. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. J Infect Dis. 1998;177(3):770-773.PubMedCrossRefGoogle Scholar
  20. 20.
    Englund JA et al. Herpes simplex virus resistant to acyclovir: a study in a tertiary care center. Ann Intern Med. 1990;112(6): 416-422.PubMedGoogle Scholar

Additional Reading

  1. Gilbert et al. The Sanford Guide to Antimicrobial Therapy 2007. 37th ed. Sperryville: Antimicrobial Therapy; 2007.Google Scholar
  2. Hall JB, Schmidt GA, and Wood LDH (eds). Principles of antimicrobial therapy and the clinical pharmacology of antimicrobial drugs. In: Principles of Critical Care. 3rd ed. New York: McGraw-Hill; 2005 [chapter 45].Google Scholar
  3. Keating MR. Antiviral agents for non-human immunodeficiency virus infections. Symposium on antimicrobial agents-Part XV. Mayo Clin Proc. 1999;74(12):1266-1283.PubMedCrossRefGoogle Scholar
  4. Mandell GL, Bennett JE, Dolin R. Principles and Practice of Infectious Diseases. 6th ed. Philadelphia: Churchill Livingstone; 2005.Google Scholar
  5. Patel R. Antifungal agents. Part I. Amphotericin B preparations and flucytosine. Mayo Clin Proc. 1998;73(12):1205-1225.Google Scholar
  6. Spanakis EK et al. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis. 2006;43(8):1060-1068.PubMedCrossRefGoogle Scholar
  7. Terrell CL. Antifungal agents. Part II. The azoles. Mayo Clin Proc. 1999;74(1):78-100.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Edward J. Blanchard
    • 1
  • Rafik Samuel
    • 1
  • Wissam Chatila
    • 2
  1. 1.Section of Infectious DiseasesTemple University School of MedicinePhiladelphiaUSA
  2. 2.Division of Pulmonary and Critical Care MedicineTemple University School of MedicinePhiladelphiaUSA

Personalised recommendations